Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
33.97
-0.97 (-2.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Corcept Therapeutics
< Previous
1
2
3
Next >
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
June 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 03, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 28, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
January 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Court Finds Corcept Therapeutics’ Patents Not Infringed
January 02, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
November 01, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Appoints Monica Tellado as President, Emerging Markets
November 01, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
October 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 25, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Inc. (NASDAQ: CORT) Sets New 52-Week High in Wednesday Session
August 23, 2023
Via
Investor Brand Network
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
August 02, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
July 17, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
June 27, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 03, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 26, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Announces Final Results of Tender Offer
April 05, 2023
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.